HOFBF (Hofseth BioCare ASA) Debt-to-EBITDA : -4.68 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOFBF Hofseth BioCare ASA HOFBF
51 GF Score
Price $0.17
GF Value $0.26
! 6 Warning Signs
View Full Analysis

What is Hofseth BioCare ASA Debt-to-EBITDA?

Hofseth BioCare ASA HOFBF 51 Debt-to-EBITDA is -4.68 as of Mar. 2026. GuruFocus rates HOFBF with a GF Score™ of 51/100 and a GF Value™ of $0.26. The stock has 6 warning signs investors should review. Among 1,549 Consumer Packaged Goods companies, Hofseth BioCare ASA ranks worse than 64557.71% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hofseth BioCare ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $13.86 Mil. Hofseth BioCare ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $22.72 Mil. Hofseth BioCare ASA's annualized EBITDA for the quarter that ended in Mar. 2026 was $-7.82 Mil. Hofseth BioCare ASA's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was -4.67.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Hofseth BioCare ASA's Debt-to-EBITDA or its related term are showing as below:

HOFBF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.96   Med: -1.56   Max: 9.54
Current: -4.91

During the past 13 years, the highest Debt-to-EBITDA Ratio of Hofseth BioCare ASA was 9.54. The lowest was -4.96. And the median was -1.56.

HOFBF's Debt-to-EBITDA is ranked worse than
100% of 1549 companies
in the Consumer Packaged Goods industry
Industry Median: 2.08 vs HOFBF: -4.91

Hofseth BioCare ASA  (OTCPK:HOFBF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Hofseth BioCare ASA Debt-to-EBITDA Related Terms


Hofseth BioCare ASA Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Hofseth BioCare ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hofseth BioCare ASA Debt-to-EBITDA Chart

Hofseth BioCare ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -1.07 -4.48 -2.45 -4.96

Hofseth BioCare ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.04 -7.26 -5.44 -2.94 -4.68

HOFBF vs KHC, GIS, HRL: Debt-to-EBITDA Comparison

For the Packaged Foods subindustry, Hofseth BioCare ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hofseth BioCare ASA Debt-to-EBITDA vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Hofseth BioCare ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hofseth BioCare ASA's Debt-to-EBITDA falls into.


HOFBF
51GF Score
Hofseth BioCare ASA HOFBF
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hofseth BioCare ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hofseth BioCare ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.996 + 22.617) / -7.179
=-4.96

Hofseth BioCare ASA's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(13.86 + 22.717) / -7.824
=-4.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -4.68 mean?
Hofseth BioCare ASA (HOFBF) has a Debt-to-EBITDA of -4.68 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hofseth BioCare ASA. According to the industry distribution chart, Hofseth BioCare ASA ranks #999999 out of 1549 companies in the Consumer Packaged Goods industry.
Is Hofseth BioCare ASA's Debt-to-EBITDA too high?
Hofseth BioCare ASA's current Debt-to-EBITDA is -4.68. Based on the distribution chart, Hofseth BioCare ASA ranks #999999 out of 1549 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Hofseth BioCare ASA has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Hofseth BioCare ASA's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Hofseth BioCare ASA ranks #999999 out of 1549 companies for Debt-to-EBITDA. This places Hofseth BioCare ASA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.08, based on 1,549 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hofseth BioCare ASA. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hofseth BioCare ASA's current Debt-to-EBITDA is -4.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hofseth BioCare ASA stock overvalued right now?
Hofseth BioCare ASA (HOFBF) has a current Debt-to-EBITDA of -4.68. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.9% below its estimated fair value. The current Debt-to-EBITDA is -4.68. Hofseth BioCare ASA's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hofseth BioCare ASA (HOFBF), the current Debt-to-EBITDA is -4.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hofseth BioCare ASA (HOFBF) Overvalued in 2026?

Based on GuruFocus' analysis, Hofseth BioCare ASA stock appears to be undervalued. The current stock price of $0.17 is trading 35.9% below its estimated GF Value™ of $0.26.

Key valuation signals for HOFBF:

  • Debt-to-EBITDA: -4.68
  • GF Value™: $0.26 vs. price of $0.17 (35.9% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the HOFBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hofseth BioCare ASA Business Description

Address Keiser Wilhelmsgate 24, Aalesund, NOR, 6003
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its brands, which also generate revenue, include salmon oil (OmeGo), water-soluble protein (ProGo), calcium/collagen (CalGo and NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
51GF Score

Get the complete analysis for HOFBF

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price
$0.26
GF Value